Business Context and Reporting Period
Company: PDF Solutions, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 10, 2013
Event: Entry into a Material Definitive Agreement (Second Amendment to Office Lease).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details specific lease obligations:
- Additional Space: 2,391 square feet added to headquarters for a device characterization wafer testing lab.
- Security Deposit: $4,232.07 (added to existing deposit).
- Lease Term: October 10, 2013, through September 30, 2018, with renewal options.
Material Changes and Lease Terms
The Company amended its lease with Legacy Partners I Riverpark I LLC to expand its footprint. The rental rate for the additional space escalates annually as follows:
| Period | Monthly Base Rent | Rate per Sq. Ft. |
|---|---|---|
| 12/1/13 - 11/30/14 | $3,945.15 | $1.65 |
| 12/1/14 - 11/30/15 | $4,016.88 | $1.68 |
| 12/1/15 - 11/30/16 | $4,088.61 | $1.71 |
| 12/1/16 - 11/30/17 | $4,160.34 | $1.74 |
| 12/1/17 - 9/30/18 | $4,232.07 | $1.77 |
Additional Obligations: The Company is responsible for improvements, operating expenses, utilities, maintenance, repairs, taxes, and insurance related to the additional space.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary risk disclosed is the commitment to fixed rental payments and associated operating costs for the new laboratory space through 2018.
Investor Verification Checklist
- Verify the total square footage of the Company's headquarters post-expansion.
- Confirm the impact of the new lease on the Company's operating cash flow and fixed cost structure.
- Review the full text of the Second Amendment (Exhibit 10.9) for specific clauses regarding termination, subletting, or further cost escalations not summarized here.
- Assess the strategic necessity of the new device characterization wafer testing lab relative to current R&D pipelines.